Barclays’s Nymox Pharmaceutical Corp NYMX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q4 | – | Sell |
-5,046
| Closed | -$10K | – | 3945 |
|
|
2021
Q3 | $10K | Sell |
5,046
-3,861
| -43% | -$7.65K | ﹤0.01% | 3756 |
|
|
2021
Q2 | $14K | Sell |
8,907
-26,451
| -75% | -$41.6K | ﹤0.01% | 3794 |
|
|
2021
Q1 | $79K | Buy |
35,358
+21,706
| +159% | +$48.5K | ﹤0.01% | 3434 |
|
|
2020
Q4 | $34K | Sell |
13,652
-5,278
| -28% | -$13.1K | ﹤0.01% | 3298 |
|
|
2020
Q3 | $47K | Sell |
18,930
-2,639
| -12% | -$6.55K | ﹤0.01% | 3321 |
|
|
2020
Q2 | $77K | Buy |
+21,569
| New | +$77K | ﹤0.01% | 3226 |
|
|
2019
Q3 | – | Sell |
-1
| Closed | – | – | 4514 |
|
|
2019
Q2 | $0 | Sell |
1
-9,260
| -100% | – | ﹤0.01% | 4511 |
|
|
2019
Q1 | $18K | Buy |
9,261
+8,762
| +1,756% | +$17K | ﹤0.01% | 3932 |
|
|
2018
Q4 | $0 | Sell |
499
-11,801
| -96% | – | ﹤0.01% | 4494 |
|
|
2018
Q3 | $30K | Buy |
12,300
+9,929
| +419% | +$24.2K | ﹤0.01% | 3860 |
|
|
2018
Q2 | $8K | Sell |
2,371
-4,508
| -66% | -$15.2K | ﹤0.01% | 3951 |
|
|
2018
Q1 | $28K | Buy |
6,879
+1,332
| +24% | +$5.42K | ﹤0.01% | 3750 |
|
|
2017
Q4 | $19K | Buy |
5,547
+4,842
| +687% | +$16.6K | ﹤0.01% | 3719 |
|
|
2017
Q3 | $3K | Sell |
705
-3,517
| -83% | -$15K | ﹤0.01% | 3824 |
|
|
2017
Q2 | $18K | Buy |
+4,222
| New | +$18K | ﹤0.01% | 3305 |
|